Publications

Manuscripts

Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri B, Sanyal A. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study. Contemporary Clinical Trials, October 2017; 61: 33-38. 

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW. A Real-World Observational Cohort of Patients with Primary Biliary Cholangitis: TARGET-PBC Study Design and Rationale. Hepatology Communications, Mar 2018;2(4) 484-491.

Posters/Presentations

Marlyn J. Mayo, Christopher L. Bowlus, Elizabeth J. Carey, Ester C. Little, Karen Deane, Richard Zink, Robert Sandefur, W. Ray Kim, Cynthia Levy. Primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome: Characteristics and response to obeticholic acid (OCA) in TARGET-PBC, a diverse, large United States (US) real- world cohort. DDW. San Diego, California. Poster presented May 2019.

Cynthia Levy, Marlyn J. Mayo, Elizabeth J. Carey, Ester C. Little, W. Ray Kim, Karen Deane, Richard Zink, Robert Sandefur, Christopher L. Bowlus. Change in Lipids: Characteristics and Response to Obeticholic Acid (OCA) in TARGET-PBC, a Diverse, Large United States (US) Real-world Cohort. DDW. San Diego, California. Poster presented May 2019.

Carey EJ, Levy C, Mayo MJ, Bowlus CL, Deane K, Sandefur RA, Laliberte PH, Zink RC and Kim WR. Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC). AASLD. San Francisco, California. Poster presented November, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. DDW. Washington, DC. Poster presented June, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. DDW. Washington, DC. Poster presented June, 2018.

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Iloeje U, Erickson M, Strauss M, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC. EASL. Paris, France. Poster presented April, 2018. 

Levy C, Bowlus CL, Carey EJ, DeMuth G, Deane K, Mayo MJ, Kim WR, Bacon BR, Bernstein D, Thuluvath PJ, Weiss LM, Fried MW. Primary Biliary Cholangitis (PBC) in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-PBC. EASL, Paris, France. Poster presented April, 2018. 

AS Barritt IV, AS Lok, KR Reddy, LM Weiss, RJ Firpi, PJ Thuluvath, HN Trinh, S Djedjos, R Haubrich, A Billin, B Koch II, R Zink, AJ Sanyal, K Cusi, BA Neuschwander-Tetri. Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort. AASLD. Boston, Massachusetts. Poster presented November 2019.

Bryan Rudolph, Jacob Bilhartz, Cheryl Schoen, Praveen Selvakumar, Sirish Palle, Stavra Xanthakos, Patrick McKiernan, Alisha Mavis, A Sidney Barritt, Miriam Vos. Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH. AASLD. Boston, Massachusetts. Poster presented November 2019. 

A. Sidney Barritt, Stephanie Watkins, Brent Neuschwander-Tetri, Cheryl Schoen, Roshani Desai, Miriam Vos, Laura Malahias, Miguel Malespin, Philip Newsome, Rajender Reddy, Jawahar Taunk, Roberto Firpi, Arun Sanyal. Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH. AASLD. Boston, Massachusetts. Poster presented November 2019. 

Vandana Khungar, Anna S. Lok,  L. Michael Weiss, Paul Thuluvath, Kalyan Ram Bhamidimarri, Derek Gazis,  Laura Malahias, K. Rajender Reddy. The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease. EASL Vienna, Austria.  Poster presented April, 2019.

Andrew M. Moon, Anna S. Lok, Roberto J. Firpi-Morell, K. Vandana Khungar, Huy Ngoc Trinh, Justin T. Kupec, Cheryl Schoen, Laura Malahias, A. Sidney Barritt. Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity.  EASL Vienna, Austria.  Poster presented April, 2019.

Ethan Weinberg, Huy N. Trinh, Roberto J Firpi, Kalyan Ram Bhamidimarri, Samuel Klein, Laura Malahias, Richard C. Zink, Anna Lok. Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD. EASL Vienna, Austria. Poster presented April, 2019.

Desai R, Tetri B et al. Characterization of polypharmacy in patients with NAFLD. Accepted for poster presentation at AASLD in San Francisco, CA. November, 2018.

Cusi K, Barritt AS, Firpi R, Klein S, Lok AS, Loomba R, Malahias L, Reddy KR, Schoen C, Taunk J, Neuschwander-Tetri BA, Wyne K, Sanyal AJ. Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM). ADA. Orlando, Florida. Poster presented June, 2018.

Palle S, Bilhartz J, Lavine J, Malahias L, Miloh T, Rudolph B, Schoen C, Xanthakos SA, McKiernan P, Vos MB. Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH. DDW. Washington, DC. Poster presented June, 2018.

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen C, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. DDW. Washington, DC. Poster presented June, 2018.

deLemos A, Barritt AS, Bhamidimarri KR, Landis C, Malahias L, Malespin M, Schoen C, Taunk J, Thuluvath P, Trinh HN, Neuschwander-Teteri BA. Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH. DDW. Washington, DC. Poster presented June, 2018.

Vos MB, Bilhartz J, Malahias L, McKiernan P, Miloh T, Palle S, Rudolph B, Schoen C, Xanthakos SA. ALT Elevation in Children with Nonalcoholic Fatty Liver Disease Commonly Surpasses Levels Reported in the Literature. Pediatric Academic Societies Meeting, Toronto, Canada. Presentation May, 2018.

Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Newschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AMCP, Boston, MA. Poster presented April, 2018.

Sanyal A, Cusi K, Firpi-Morell R, Gitlin N, Levy C, Malahias L, Reddy KR, Schoen CL, Weiss LM, Lok AS. Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease. EASL, Paris, France. Poster presented April, 2018.

Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JEM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. NASH-TAG Conference. Park City, Utah. Poster presented January, 2018.

Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. HEP DART Conference, Kona, Hawaii. Poster presented December, 2017.

Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, DeMuth GE, Crawford JM, Reddy KR, Trinh HN, Vos MB, Weiss M, Cusi K, Neuschwander-Tetri BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease in the U.S.: Clinical Characteristics of Patients Enrolled in TARGET-NASH. AASLD, Washington, DC. Poster presented October, 2017.

Vos MB. The Trans-Atlantic Pediatric TARGET-NASH Study: Advancing Clinical Care for Pediatric NAFLD. International Conference on Fatty Liver, Seville, Spain. Presentation June, 2017.

Barritt SA, Cusi K, Klein S, Crawford JEM, DeMuth GE, Malahias L, Neuschwander-Tetri BA, Sanyal A, Vos, MB. Design and Rationale for a Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. International Conference on Fatty Liver, Seville, Spain. Poster presented June, 2017.

Vos MB. A real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017, Washington, DC. Presentation May, 2017.

Vos MB, Barritt AS, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A. A Real World Observational Cohort of Patients with Nonalcoholic Fatty Liver Disease: The TARGET-NASH Study. NASH Biomarkers Workshop 2017, Washington DC. Poster presented May, 2017.

Roniel Cabrera, Amit Singal, Massimo Colombo, Anthony El-Khoueiry, R. Kate Kelley, Hannah Lee, Laura Malahias, Tim Meyer, Pippa Newell, Neehar Parikh, Bruno Sangro, K Rajender Reddy, Richard Zink, Adrian Di Bisceglie.  Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC). Poster presented at EASL, Vienna, Austria, April 2019.

Neehar D. Parikh, Laura Malahias, Robert S Brown Jr., Roniel Cabrera, Patricia Denise Jones, Charles Landis, Hannah Lee, Parvez Mantry, Edward Mena, Nishant Poddar, K. Rajender Reddy, Roshan Shrestha, Paul Thuluvath, Richard C. Zink, Amit G. Singal. Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US.  ASCO-GI. San Francisco, California.  Presented January 2019.

Parikh N, Singal A, et al. Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States. Accepted for poster presentation at ASCO GI in San Francisco, CA. January, 2019.

Edward L. Barnes, John S. Hanson, Miguel Regueiro, Sumona Saha, Bruce E. Sands, David T. Rubin, Marla C. Dubinsky, Corey A. Siegel, Derek R. Gazis, Julie M. Crawford, Millie D. Long. Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort. ACG. San Antonio, Texas. Poster presented October, 2019. Presidential Poster Award 

Nitin Gupta, Bruce E. Sands, Miguel Regueiro, Marla C. Dubinsky, David T. Rubin, John S. Hanson, Faten Aberra, Michael Weiss, Stephanie Watkins, Derek Gazis, Millie D. Long. Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study. ACG. San Antonio, Texas. Poster presented October, 2019.

Long M, Sands B et al. Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD. ACG, Philadelphia, Pennsylvania. Poster presented October, 2018.

DE Bernstein, HN Trinh, ER Schiff, CI Smith, RC Zink, AS Lok. Effectiveness of Tenofovir Alafenamide in Patients with Chronic Hepatitis B Treated in Usual Clinical Practice: Results from the TARGET-HBV Observational Cohort Study. AASLD. Boston, Massachusetts. Poster presented November 2019.